OPPS
This article was originally published in The Gray Sheet
Executive Summary
Datascope's collagen-based Vasoseal is not included on the Health Care Financing Administration's list of devices eligible for reimbursement under the hospital outpatient prospective payment system. Competitor Kensey-Nash's Angioseal closure device is included on the list. St. Jude acquired marketing and manufacturing rights to Angioseal in February 1999 (1"The Gray Sheet" Feb. 8, 1999, p. 15). "The Gray Sheet" previously reported the device was not on the list
You may also be interested in...
St. Jude's $167 Mil. Angio-Seal Puncture Closure Buy Adds $50 Mil. In Sales
St. Jude's $167 mil. cash acquisition of marketing and manufacturing rights to Kensey Nash's Angio-Seal hemostatic puncture closure device from Tyco International would "more than double" sales into the cardiology cath lab by St. Jude's Daig division and add 60 to its sales and marketing staff, the firm states.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.